StockNews.com lowered shares of Aurinia Pharmaceuticals (NASDAQ:AUPH - Free Report) TSE: AUP from a strong-buy rating to a buy rating in a research note issued to investors on Monday morning.
Aurinia Pharmaceuticals Stock Down 2.2 %
Shares of Aurinia Pharmaceuticals stock traded down $0.18 during trading on Monday, reaching $7.80. The company had a trading volume of 699,389 shares, compared to its average volume of 1,263,423. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -51.96 and a beta of 1.22. The firm's fifty day moving average is $8.52 and its 200-day moving average is $7.61. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. Aurinia Pharmaceuticals has a fifty-two week low of $4.71 and a fifty-two week high of $10.67.
Institutional Investors Weigh In On Aurinia Pharmaceuticals
Institutional investors have recently modified their holdings of the stock. Invesco Ltd. raised its stake in Aurinia Pharmaceuticals by 1.0% during the fourth quarter. Invesco Ltd. now owns 144,112 shares of the biotechnology company's stock worth $1,294,000 after acquiring an additional 1,421 shares during the period. Teacher Retirement System of Texas raised its stake in Aurinia Pharmaceuticals by 5.9% during the fourth quarter. Teacher Retirement System of Texas now owns 36,098 shares of the biotechnology company's stock worth $324,000 after acquiring an additional 2,020 shares during the period. Tower Research Capital LLC TRC raised its stake in Aurinia Pharmaceuticals by 368.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 2,635 shares during the period. SBI Securities Co. Ltd. acquired a new stake in Aurinia Pharmaceuticals during the fourth quarter worth about $25,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in Aurinia Pharmaceuticals by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 30,359 shares of the biotechnology company's stock worth $273,000 after acquiring an additional 2,857 shares during the period. Institutional investors and hedge funds own 36.83% of the company's stock.
About Aurinia Pharmaceuticals
(
Get Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Featured Stories
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
